TrialAmerican journal of hematology2017

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.

Thomas E Witzig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.